Peptides and peptide-loaded antigen presenting cells for the activation of ctl
CA 2278189 A1 · Owner: Epimmune, Inc. · Inventors: Sette, Alessandro; Tsai, Van; Celis, Estaban
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods for generating antigen-specific cytotoxic T lymphocytes (CTLs) in vitro are presented in conjuntion with methods for using these CTLs for therapy in vivo. The antigen presenting cells (APCs) used herein notably include dentritic cells pretreated with GM-CSF and IL-4. Antigen-specific CTLs were obtained by incubating CD8 preparations in the presence of APCs that bound desired peptides. IL-7 was generally added at day 1 of the incubation; IL-10 was generally added one day later and during restimulation. The invention also comprises methods for using peptide pulsed dentritic cells to identify novel MHC Class I-restricted tumor antigens and subdominant epitopes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 30, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 30, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 30, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.